NasdaqGS:XERS

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. More Details


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Xeris Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XERS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: XERS's weekly volatility has decreased from 18% to 11% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-7.3%

XERS

-1.4%

US Pharmaceuticals

1.8%

US Market


1 Year Return

-50.7%

XERS

5.4%

US Pharmaceuticals

20.4%

US Market

Return vs Industry: XERS underperformed the US Pharmaceuticals industry which returned 5.4% over the past year.

Return vs Market: XERS underperformed the US Market which returned 19% over the past year.


Shareholder returns

XERSIndustryMarket
7 Day-7.3%-1.4%1.8%
30 Day-22.3%0.2%6.0%
90 Day9.6%-2.4%6.8%
1 Year-50.7%-50.7%8.1%5.4%23.2%20.4%
3 Yearn/a24.3%15.2%47.4%37.6%
5 Yearn/a35.0%19.4%91.9%70.8%

Long-Term Price Volatility Vs. Market

How volatile is Xeris Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xeris Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XERS ($4.32) is trading below our estimate of fair value ($73.56)

Significantly Below Fair Value: XERS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XERS is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: XERS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XERS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XERS is overvalued based on its PB Ratio (14.1x) compared to the US Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is Xeris Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

61.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XERS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XERS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XERS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XERS's revenue (50.4% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: XERS's revenue (50.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XERS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xeris Pharmaceuticals performed over the past 5 years?

-46.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XERS is currently unprofitable.

Growing Profit Margin: XERS is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XERS is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.

Accelerating Growth: Unable to compare XERS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XERS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).


Return on Equity

High ROE: XERS has a negative Return on Equity (-714.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xeris Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: XERS's short term assets ($163.2M) exceed its short term liabilities ($27.0M).

Long Term Liabilities: XERS's short term assets ($163.2M) exceed its long term liabilities ($129.0M).


Debt to Equity History and Analysis

Debt Level: XERS's debt to equity ratio (832.8%) is considered high.

Reducing Debt: Insufficient data to determine if XERS's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XERS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XERS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Xeris Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XERS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XERS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XERS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XERS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Paul Edick (64 yo)

3.83yrs

Tenure

US$4,307,638

Compensation

Mr. Paul R. Edick has been the Chief Executive Officer and Director of Xeris Pharmaceuticals, Inc. since January 10, 2017 and has been its Chairman since June 2018. He served as President at Xeris Pharmace...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD4.31M) is above average for companies of similar size in the US market ($USD1.12M).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO3.83yrsUS$4.31m0.28%
$ 586.7k
John Shannon
President & COO0.25yrUS$1.27m0.11%
$ 242.9k
Beth Hecht
Senior VP2.83yrsUS$775.57k0.032%
$ 68.3k
Steven Prestrelski
Co-Founder & Chief Scientific Officerno datano data0.86%
$ 1.8m
Barry Deutsch
Chief Financial Officer2.58yrsUS$948.18k0.088%
$ 186.1k
Allison Wey
Senior Vice President of Investor Relations & Corporate Communications2.33yrsno datano data
Kenneth Johnson
Senior Vice President of Clinical Development3.83yrsno data0.014%
$ 29.8k
Kevin McCulloch
Senior Vice President of Global Operations & Business Developmentno datano datano data

2.7yrs

Average Tenure

56.5yo

Average Age

Experienced Management: XERS's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul Edick
Chairman & CEO3.83yrsUS$4.31m0.28%
$ 586.7k
John Brooks
Scientific Advisory Board Memberno datano datano data
Orville Kolterman
Member of Scientific Advisory Boardno datano datano data
Jeffrey Sherman
Independent Non-Executive Board Member2.58yrsUS$160.36k0%
$ 0
John Schmid
Lead Independent Director1.75yrsUS$192.36k0.012%
$ 24.4k
W. Ward
Member of Scientific Advisory Boardno datano datano data
Mark Thierer
Independent Non-Executive Board Member1.08yrsUS$118.60k0%
$ 0
Marla Persky
Independent Non-Executive Board Member2.58yrsUS$166.36k0%
$ 0
Morey Haymond
Scientific Advisory Board Memberno datano datano data
Barbar-Jean Bormann-Kennedy
Independent Non-Executive Board Member2.58yrsUS$170.36k0%
$ 0
Dawn Halkuff
Independent Non-Executive Board Member2.58yrsUS$160.36k0%
$ 0

2.6yrs

Average Tenure

64yo

Average Age

Experienced Board: XERS's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 81.4%.


Top Shareholders

Company Information

Xeris Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xeris Pharmaceuticals, Inc.
  • Ticker: XERS
  • Exchange: NasdaqGS
  • Founded: 2005
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$211.578m
  • Shares outstanding: 48.98m
  • Website: https://www.xerispharma.com

Number of Employees


Location

  • Xeris Pharmaceuticals, Inc.
  • 180 North LaSalle Street
  • Suite 1600
  • Chicago
  • Illinois
  • 60601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XERSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
2B3DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation techno...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/24 23:45
End of Day Share Price2020/11/24 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.